Cryptococcal therapies and drug targets: the old, the new and the promising.
Cryptococcal therapies and drug targets: the old, the new and the promising.
复制标题
DOI:
10.1111/cmi.12590
复制
发表时间:
2016-06
影响因子:
3.4
通讯作者:
Casadevall A
中科院分区:
文献类型:
--
作者:
Coelho C;Casadevall A
Half a century after the introduction of Amphotericin B the management of cryptococcosis remains unsatisfactory. The disease, caused primarily by the two fungal species Cryptococcus neoformans and Cryptococcus gattii, remains responsible for considerable morbidity and mortality despite standard medical care. Current therapeutic options are limited to Amphotericin B, azoles and 5-flucytosine. However, this organism has numerous well-characterized virulence mechanisms that are amenable to pharmacological interference and are thus potential therapeutic targets. Here, we discuss existing approved antifungal drugs, resistance mechanisms to these drugs and non-standard antifungal drugs that have potential in treatment of cryptococcosis, including immunomodulatory strategies that synergize with antifungal drugs, such as cytokine administration or monoclonal antibodies. Finally, we summarize attempts to target well-described virulence factors of Cryptococcus, the capsule or fungal melanin. This review emphasizes the pressing need for new therapeutic alternatives for cryptococcosis.
登录
查看更多内容
影响因子:
3.6
作者:
Gilbert NM;Donlin MJ;Gerik KJ;Specht CA;Djordjevic JT;Wilson CF;Sorrell TC;Lodge JK
通讯作者:
Lodge JK
DOI:
10.1534/g3.112.004242
发表时间:
2013-03
期刊:
G3 (Bethesda, Md.)
影响因子:
--
作者:
Chen YL;Lehman VN;Lewit Y;Averette AF;Heitman J
通讯作者:
Heitman J
影响因子:
3.3
作者:
Cavaleiro, Carlos;Salgueiro, Ligia;Pinto, Eugenia
通讯作者:
Pinto, Eugenia
影响因子:
3.1
作者:
Cox, GM;Mukherjee, J;Perfect, JR
通讯作者:
Perfect, JR
影响因子:
3.6
作者:
El Amraoui, B;El Amraoui, M;Fassouane, A
通讯作者:
Fassouane, A